The oral antisense oligonucleotide monarsen [EN 101] appears to be beneficial in the treatment of myasthenia gravis

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1605, 2007-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunomodulatory treatment for myasthenia gravis

By  

Inpharma, Vol. 1, Iss. 1283, 2001-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Treatment strategies for myasthenia gravis: an update

By Díaz-Manera Jordi   Rojas García Ricard   Illa Isabel  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 13, 2012-09 ,pp. : 1873-1883

Informa Healthcare

Access to resources Recommend Favorite

Treatment of Myasthenia Gravis: Focus on Pyridostigmine

By Maggi Lorenzo   Mantegazza Renato  

Clinical Drug Investigation, Vol. 31, Iss. 10, 2011-10 ,pp. : 691-701

Adis International

Access to resources Recommend Favorite

Ciclosporin is effective in the treatment of patients with severe myasthenia gravis

By  

Inpharma, Vol. 1, Iss. 1489, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Zileuton appears beneficial in the treatment of patients with atopic dermatitis

By  

Inpharma, Vol. 1, Iss. 1225, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite